ATE393629T1 - Verwendung von cci-779 als antineoplastisches mittel - Google Patents

Verwendung von cci-779 als antineoplastisches mittel

Info

Publication number
ATE393629T1
ATE393629T1 AT01996175T AT01996175T ATE393629T1 AT E393629 T1 ATE393629 T1 AT E393629T1 AT 01996175 T AT01996175 T AT 01996175T AT 01996175 T AT01996175 T AT 01996175T AT E393629 T1 ATE393629 T1 AT E393629T1
Authority
AT
Austria
Prior art keywords
cci
antineoplastic agent
antineoplastic
agent
Prior art date
Application number
AT01996175T
Other languages
English (en)
Inventor
Gary Dukart
James Gibbons
Lisa Speicher
Philip Frost
Carolyn Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE393629T1 publication Critical patent/ATE393629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01996175T 2000-11-15 2001-11-13 Verwendung von cci-779 als antineoplastisches mittel ATE393629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15

Publications (1)

Publication Number Publication Date
ATE393629T1 true ATE393629T1 (de) 2008-05-15

Family

ID=22941961

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996175T ATE393629T1 (de) 2000-11-15 2001-11-13 Verwendung von cci-779 als antineoplastisches mittel

Country Status (27)

Country Link
US (3) US20020091137A1 (de)
EP (1) EP1335725B1 (de)
JP (4) JP4472251B2 (de)
KR (1) KR100827942B1 (de)
CN (2) CN102058588A (de)
AR (1) AR031341A1 (de)
AT (1) ATE393629T1 (de)
AU (2) AU2731302A (de)
BR (1) BR0115323A (de)
CA (1) CA2429020C (de)
CY (1) CY1108109T1 (de)
DE (1) DE60133831T2 (de)
DK (1) DK1335725T3 (de)
EA (1) EA007096B1 (de)
ES (1) ES2305134T3 (de)
HU (1) HUP0400521A3 (de)
IL (2) IL155871A0 (de)
MX (1) MXPA03004192A (de)
NO (1) NO20032181L (de)
NZ (1) NZ539668A (de)
PL (1) PL207061B1 (de)
PT (1) PT1335725E (de)
SG (1) SG148031A1 (de)
SI (1) SI1335725T1 (de)
TW (1) TWI286074B (de)
WO (1) WO2002040000A2 (de)
ZA (1) ZA200304603B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2762140T (lt) 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
WO2002098416A2 (en) * 2001-06-01 2002-12-12 Wyeth Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
BR0307544A (pt) * 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
JP2005531391A (ja) * 2002-06-27 2005-10-20 微創医療器械（上海）有限公司 薬剤放出ステント
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
WO2004072265A2 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20040258662A1 (en) * 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
CA2523798A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
MXPA05013865A (es) * 2003-07-25 2006-02-28 Wyeth Corp Formulaciones liofilizadas de cci-779.
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
DK1701698T3 (da) * 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
EP2275103B1 (de) * 2005-11-21 2014-04-23 Novartis AG mTOR-Inhibitoren in der Behandlung endokriner Tumore
EP1962819A1 (de) * 2005-12-20 2008-09-03 Wyeth Steuerung der formstabilität einer cci-779-dosierung durch steuerung der unreinheiten von wirkstoffen
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
CA2709413C (en) * 2007-10-03 2017-09-12 Genesis Technical Systems Corp. Dynamic, asymmetric rings
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2278966B1 (de) 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
JP2013527223A (ja) * 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
KR101965319B1 (ko) * 2015-08-24 2019-04-04 샨시 야바오 헬스 프로덕츠 컴퍼니 리미티드 항종양 약물 제조에서의 다이하이드록시아세톤의 용도
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
SG43072A1 (en) 1991-06-18 1997-10-17 American Home Prod Method of treating adult t-cell leukemia/lymphoma
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
ES2228932T3 (es) 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
CY1108109T1 (el) 2014-02-12
PL362740A1 (en) 2004-11-02
WO2002040000A3 (en) 2002-09-06
DE60133831T2 (de) 2009-05-20
SG148031A1 (en) 2008-12-31
JP2004517065A (ja) 2004-06-10
EP1335725A2 (de) 2003-08-20
DE60133831D1 (de) 2008-06-12
US7189735B2 (en) 2007-03-13
JP4472251B2 (ja) 2010-06-02
ES2305134T3 (es) 2008-11-01
CN102058588A (zh) 2011-05-18
AU2007201324B2 (en) 2010-11-18
EP1335725B1 (de) 2008-04-30
ZA200304603B (en) 2004-09-13
PL207061B1 (pl) 2010-10-29
NO20032181D0 (no) 2003-05-14
EA007096B1 (ru) 2006-06-30
US20030153593A1 (en) 2003-08-14
JP2010018620A (ja) 2010-01-28
TWI286074B (en) 2007-09-01
AU2731302A (en) 2002-05-27
IL155871A0 (en) 2003-12-23
US7781446B2 (en) 2010-08-24
AR031341A1 (es) 2003-09-17
CA2429020C (en) 2009-05-26
US20070142425A1 (en) 2007-06-21
MXPA03004192A (es) 2003-09-22
CA2429020A1 (en) 2002-05-23
JP2016094444A (ja) 2016-05-26
NZ539668A (en) 2007-06-29
HUP0400521A3 (en) 2007-05-29
NO20032181L (no) 2003-05-14
US20020091137A1 (en) 2002-07-11
WO2002040000A2 (en) 2002-05-23
HUP0400521A2 (hu) 2004-06-28
CN1678312A (zh) 2005-10-05
JP2014088430A (ja) 2014-05-15
BR0115323A (pt) 2004-02-17
SI1335725T1 (sl) 2008-08-31
KR100827942B1 (ko) 2008-05-13
EA200300566A1 (ru) 2003-10-30
KR20040029309A (ko) 2004-04-06
AU2007201324A1 (en) 2007-04-19
DK1335725T3 (da) 2008-06-30
PT1335725E (pt) 2008-06-19
HK1058008A1 (en) 2004-04-30
IL155871A (en) 2012-03-29

Similar Documents

Publication Publication Date Title
DE60133831D1 (de) Verwendung von cci-779 als antineoplastisches mittel
ATE391531T1 (de) Schweisshemmende mittel
DE60214413D1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
DE60039194D1 (de) 3-aminochinazolin-2,4-dione als antibakterielle mittel
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE359275T1 (de) Substituierte bizyclische derivate verwendbar als antitumor mittel
ATE319686T1 (de) Mutilin-derivate und ihre anwendung als antibakterielle mittel
DE60134094D1 (de) C7-taxanester als antitumormittel
DE60127997D1 (de) 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika
DE60132618D1 (de) 4,6-diphenylpyridinderivate als entzündungshemmende mittel
DE60218606D1 (de) Photodetektor und sein Betriebsverfahren
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
NO20021115D0 (no) Ny sammensetning
DE69806141D1 (de) Indazoleamid-verbindungen als serotoninergene mittel
ATE437860T1 (de) 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
ATE259362T1 (de) Indolylpiperidinderivate als antihistaminische und antiallergische mittel
DE69917451D1 (de) Sulfonylbenzolverbindungen als analgetische und entzündungshemmende mittel
DE60230470D1 (de) Festes kosmetisches Mittel
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
DE69921983D1 (de) Indolderivate als serotonergische mittel
DE60120711D1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DE60107055D1 (de) Thienopyridinderivate zur verwendung als entzündungshemmende mittel
FR2791258B1 (fr) Composition amincissante

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1335725

Country of ref document: EP

REN Ceased due to non-payment of the annual fee